Vertex pauses diabetes islet cell therapy study after two patient deaths it says are unrelated to drug
Vertex has paused the Phase I/II study of its islet cell therapy for type 1 diabetes following the death of two patients, though the company said the deaths were unrelated to the experimental therapy.
Known as VX-880, the treatment is Vertex’s attempt at potentially creating a cure for type 1 diabetes, or at least a much more durable treatment than frequent insulin injections. The study will remain on pause as global regulators and an independent data monitoring committee review the “totality of the data.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
